Hawaii Biotech Inc. has been awarded a $1.1 million federal grant to continue its work into the development of anthrax anti-toxin drugs.
The initial round of funding from the National Institute of Allergy and Infectious Diseases is part of a five-year grant totalling $7.4 million. The Institute is part of the National Institutes of Health.
“Research and development of vaccines and treatments to protect against infectious diseases will help keep our families and communities healthy and safe,” said U.S. Sen. Brian Schatz.
“Hawaii Biotech is doing important work to find vaccines for some of the biggest global health threats, like anthrax, and this grant will help give them the resources they need. Achieving this competitive grant highlights Hawaii’s continued growth in the high-level research and development community.”
Hawaii Biotech is a privately held biotechnology company focused on the development of prophylactic vaccines for established and emerging infectious diseases and anti-toxin drugs for biological threats.